Ivo Kocák
Friedrich-Alexander-Universität Erlangen-Nürnberg(DE)
Publications by Year
Research Areas
Prostate Cancer Treatment and Research, Cancer Treatment and Pharmacology, Colorectal Cancer Treatments and Studies, Multiple and Secondary Primary Cancers, Cancer Immunotherapy and Biomarkers
Most-Cited Works
- → Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial(2010)3,265 cited
- → Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial(2018)406 cited
- → Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial(2018)212 cited
- → A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer(2010)185 cited
- → Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial(2013)170 cited
- Malignant melanoma associates with Th1/Th2 imbalance that coincides with disease progression and immunotherapy response.(2002)
- → PTEN loss as a predictive biomarker for the Akt inhibitor ipatasertib combined with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC)(2016)53 cited
- → Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial(2022)30 cited
- → Malignant melanoma associates with deficient IFN-induced STAT 1 phosphorylation(2003)28 cited
- → Genetic risk factors of cisplatin induced ototoxicity in adult patients(2016)25 cited